

Hereditary Breast & Ovarian Cancer (BRCA)

BRCA mutations disable critical DNA repair mechanisms, allowing cancer-causing genetic errors to accumulate unchecked in breast and ovarian tissues.

THE STORY IN ONE SENTENCE

BRCA mutations disable critical DNA repair mechanisms, allowing cancer-causing genetic errors to accumulate unchecked in breast and ovarian tissues.

“BRCA gene mutations break the body's ability to fix damaged DNA in cells. When DNA repair fails, cells can grow out of control and form breast or ovarian cancers.”

Normal anatomy — the body's job

The BRCA1 and BRCA2 genes produce proteins that repair double-strand breaks in DNA, the most dangerous type of DNA damage. These proteins work as part of a larger repair system called homologous recombination (using a matching DNA template to fix breaks accurately). Every time a cell divides or encounters damaging agents like radiation or chemicals, BRCA proteins scan for broken DNA strands and coordinate precise repairs. This surveillance and repair process prevents mutations from becoming permanent in the cell's genetic code.

BODY'S JOB

BRCA genes work like a quality-control inspector and repair crew in a factory—they constantly check the assembly line (cell division) for broken parts (DNA breaks), then use the original blueprint (the matching chromosome) to fix mistakes perfectly before the product (new cell) rolls out.

1. Cell experiences DNA damage from normal metabolism, hormones, or environmental exposures, creating a double-strand break in the DNA helix.
2. BRCA1 protein recognizes the break site and recruits other repair proteins to the damage zone within minutes.
3. BRCA2 protein loads RAD51 enzymes (DNA-repair workers) onto the broken DNA ends to stabilize them.

4. The repair complex searches for the matching undamaged DNA strand on the sister chromosome to use as a template.
5. RAD51 and BRCA2 copy the correct sequence from the template and rebuild the broken strand accurately.
6. Repaired DNA is checked for accuracy, the repair proteins detach, and the cell continues normal growth or division safely.

What breaks

People with BRCA mutations inherit one broken copy of the repair gene from a parent, so every cell in their body starts with only one working copy. Over time, if that second working copy gets damaged in breast or ovarian tissue, the cell loses all DNA-repair ability. Without working BRCA genes, double-strand DNA breaks get repaired sloppily using backup methods that introduce mistakes, and these mistakes accumulate until the cell becomes cancerous.

CLINICAL TERM

Inherited BRCA1 or BRCA2 pathogenic variants (disease-causing mutations) follow an autosomal dominant (one altered gene copy is enough to increase risk) pattern with incomplete penetrance (not everyone with the mutation develops cancer). Cells with germline BRCA mutations (mutations present from conception in all cells) require a second hit—loss of the remaining wild-type allele (normal gene copy)—to completely lose homologous recombination capacity. This triggers genomic instability (widespread DNA errors and chromosome breaks) and reliance on error-prone non-homologous end joining (NHEJ) repair, which ligates (glues) broken DNA ends together without a template, introducing deletions and translocations (chunks of DNA moved to wrong spots).

How the body compensates

Cells with one working BRCA copy often function normally for years because 50% repair capacity is usually enough for routine DNA maintenance. When both copies are lost, backup repair pathways attempt to fix DNA breaks, but these alternative systems are much less accurate and allow mutations to persist. The body's immune surveillance may destroy some abnormal cells, but repeated cycles of faulty repair eventually produce cells that evade immune detection and grow uncontrollably.

1. {'step': 'Haploinsufficiency phase', 'detail': 'With one working BRCA gene, cells perform DNA repair at roughly half-normal efficiency, which is adequate for most routine damage but creates vulnerability during times of high cell turnover like puberty, pregnancy, or hormone replacement therapy.'}

2. {'step': 'Loss of heterozygosity (LOH)', 'detail': 'The remaining normal BRCA copy is lost in a single breast or ovarian cell through mutation, deletion, or epigenetic silencing (chemical tags that turn the gene off), leaving that cell with zero functional BRCA protein.'}
3. {'step': 'Alternative repair pathway activation', 'detail': 'The cell shifts to non-homologous end joining (NHEJ) and single-strand annealing (SSA), backup systems that quickly glue broken DNA ends together without checking accuracy, introducing small mutations and chromosome rearrangements.'}
4. {'step': 'Accumulation of secondary mutations', 'detail': 'Errorprone repair creates mutations in other cancer-related genes—TP53 (cell-cycle checkpoint), PIK3CA (growth signaling), and others—transforming the cell step-by-step toward malignancy over months to years.'}
5. {'step': 'Immune surveillance and escape', 'detail': 'The immune system detects and destroys many abnormal cells through natural killer cells and T-cells, but cells that acquire mutations allowing immune evasion (like loss of HLA molecules that display abnormal proteins) survive and expand.'}
6. {'step': 'Clonal expansion', 'detail': 'The surviving abnormal cell divides repeatedly, and its descendants inherit the same repair defect plus additional mutations, forming a growing clone that eventually becomes a detectable tumor mass.'}

Domino effect

1. Germline BRCA mutation inherited at conception — Every cell in the body carries one defective BRCA gene, reducing baseline DNA-repair capacity and setting the stage for cancer if the second copy is lost.
2. Hormonal exposure amplifies DNA damage in target tissues — Estrogen and progesterone drive repeated cycles of cell division in breast and ovarian tissue over decades, and estrogen metabolites (breakdown products) create oxidative DNA damage that requires BRCA-mediated repair.
3. Second hit eliminates remaining BRCA function in one cell — Random mutation, spontaneous deletion, or accumulated oxidative stress knocks out the last working BRCA gene copy in a single epithelial cell (lining cell) in the breast duct or ovarian surface.
4. Genomic instability triggers mutation cascade — Without homologous recombination, every cell division produces new DNA breaks that are repaired incorrectly, rapidly accumulating dozens to hundreds of mutations in growth-control and DNA-damage-response genes.
5. Loss of cell-cycle checkpoints (especially TP53) — Mutations disable p53 protein (the 'guardian of the genome') and other checkpoint proteins that normally stop defective cells from dividing, allowing the cell to replicate despite carrying dangerous genetic errors.

6. Uncontrolled proliferation and tumor formation — The cell ignores normal stop signals, divides continuously, and forms a microscopic tumor cluster (carcinoma in situ) that may remain contained for months to years before breaking through the basement membrane (thin barrier around ducts or ovarian surface).
7. Invasion and metastasis — Accumulated mutations allow tumor cells to produce enzymes that dissolve surrounding tissue, enter blood vessels or lymphatic channels, and travel to distant sites—lymph nodes, bones, liver, lungs, or brain.
8. Widespread metastatic disease and organ failure — Metastatic tumors disrupt organ function by replacing normal tissue, consuming nutrients, and causing complications like bone fractures, liver failure, fluid around the lungs (pleural a fluid collection (effusion)), or brain swelling, ultimately leading to multi-organ failure and death if untreated.

Symptoms · what the patient feels, and why

- No symptoms (often discovered through genetic testing): BRCA1 or BRCA2 gene mutations increase cancer risk but do not cause symptoms until cancer develops
- Family history of early-onset breast cancer (before age 50): BRCA mutations are inherited in autosomal dominant pattern (50% chance each child gets the mutation) causing breast cancer at younger ages
- Family history of ovarian cancer at any age: BRCA mutations impair DNA repair allowing ovarian cancer cells to grow; 40-50% lifetime risk in BRCA1 carriers
- Male relative with breast cancer: BRCA2 mutations give men 6-7% lifetime breast cancer risk; BRCA1 gives 1% risk
- Multiple family members with breast or ovarian cancer on same side of family: Autosomal dominant inheritance means mutation passes through generations on maternal or paternal side
- Ashkenazi Jewish ancestry with family history: 1 in 40 Ashkenazi Jews carry founder mutations (specific BRCA changes common in this population)
- Personal history of pancreatic cancer: BRCA mutations increase pancreatic cancer risk 3-5 fold especially BRCA2
- Personal history of prostate cancer diagnosed before age 55: BRCA2 mutations increase aggressive prostate cancer risk; cells cannot repair DNA damage properly

Focused exam

- Breast examination looking for mass, skin changes, nipple discharge: Baseline clinical exam before starting enhanced screening protocol detects existing cancers that need immediate workup

- Palpable axillary (armpit) lymph nodes: Enlarged or hard lymph nodes may indicate breast cancer spread requiring urgent diagnostic imaging
- Abdominal examination for masses or fluid buildup in the belly (ascites) (fluid in belly): Ovarian cancer often presents late with abdominal mass or fluid; physical findings need immediate imaging
- Documentation of Tanner stage (puberty stage) if adolescent patient: Screening recommendations for BRCA carriers begin at age 25 but risk-reducing surgery timing depends on completion of puberty
- Measurement of height and weight for BMI (body mass index): Obesity increases baseline breast cancer risk and affects surveillance imaging quality and surgical planning
- Assessment of chest wall anatomy if prior breast surgery: Previous lumpectomy or biopsy sites affect MRI screening interpretation and surgical planning for risk reduction

Diagnostics · every test answers a question

- Genetic counseling session before testing → Does patient understand test implications, limitations, insurance impact, and family implications before consenting?
- Multi-gene panel blood test or targeted BRCA1/BRCA2 sequencing → Does patient carry pathogenic variant (disease-causing mutation) in BRCA1, BRCA2, or other cancer susceptibility genes?
- Variant classification review → Is genetic change clearly pathogenic, clearly benign, or variant of uncertain significance (VUS)?
- Annual breast MRI (magnetic resonance imaging) starting age 25-30 → Is there early breast cancer that mammogram might miss in dense breast tissue of young BRCA carriers?
- Annual mammogram starting age 30 (alternating with MRI every 6 months) → Is there breast cancer visible on x-ray, particularly calcifications (calcium deposits) MRI might miss?
- Transvaginal ultrasound and CA-125 blood test every 6 months (limited effectiveness) → Is there early ovarian cancer although screening has not proven to reduce death in BRCA carriers?
- Colonoscopy screening per guidelines → Does patient have polyps or colon cancer (some BRCA carriers may have modestly increased colon cancer risk)?
- Genetic testing of tumor tissue (if cancer develops) → Does tumor show BRCA-related features that predict response to PARP inhibitor drugs (olaparib, talazoparib)?

Treatment logic

- Risk-reducing bilateral mastectomy (removing both breasts) → Reduces breast cancer risk by 90-95%; does not eliminate risk because small amount of breast tissue remains

- Risk-reducing bilateral salpingo-oophorectomy (removing fallopian tubes and ovaries) after childbearing complete, age 35-40 → Reduces ovarian cancer risk by 80-90% and breast cancer risk by 50% if done before menopause; most effective intervention
- Chemoprevention with tamoxifen (20 milligrams daily for 5 years) in premenopausal women → Reduces estrogen-receptor-positive breast cancer risk by 40-50% but does not reduce triple-negative breast cancer common in BRCA1 carriers
- Enhanced surveillance without risk-reducing surgery (patient choice) → Increases early cancer detection so treatment can start at earlier stage with better survival; does not prevent cancer
- Genetic counseling for family members → Identifies other at-risk relatives who can benefit from testing and prevention; 50% of first-degree relatives carry mutation
- Cascade testing (testing relatives after positive result in family) → Identifies which relatives carry mutation and need high-risk management versus those who do not and can follow average-risk screening

Medications

Tamoxifen · Selective estrogen receptor modulator (SERM)

Tamoxifen blocks estrogen from attaching to breast cells. Estrogen makes some breast cancer cells grow. By blocking estrogen, tamoxifen reduces the chance that estrogen-receptor-positive breast cancer will develop in women who carry BRCA mutations.

1. Tamoxifen enters breast cells and binds to estrogen receptors (proteins that normally respond to estrogen hormone)
2. Drug blocks estrogen from attaching to receptors so estrogen cannot send growth signals
3. Without estrogen signals, breast cells that need estrogen to grow cannot multiply
4. Drug reduces development of new estrogen-receptor-positive breast cancers by 40-50% over 5 years
5. In uterus, tamoxifen acts like weak estrogen and can stimulate uterine lining growth (opposite effect)

SAFETY WATCH

Increases blood clot risk in legs (DVT) and lungs (PE) 2-3 fold, especially in first 2 years ·
Increases uterine cancer risk 2-3 fold; report any vaginal bleeding for urgent evaluation ·
Can cause menopausal symptoms including hot flashes, vaginal dryness even in premenopausal women · Do not use during pregnancy; use effective contraception; can harm developing baby

Olaparib or talazoparib · PARP inhibitor (poly ADP-ribose polymerase inhibitor)

PARP inhibitors block an enzyme that helps cells repair damaged DNA. Normal cells have backup repair systems, but BRCA mutation carriers already have broken DNA repair. Cancer cells in BRCA carriers cannot survive without PARP, so blocking PARP kills cancer cells while sparing normal cells (synthetic lethality).

1. Drug enters all cells and blocks PARP enzyme from repairing single-strand DNA breaks
2. Normal cells use BRCA1 or BRCA2 proteins to fix DNA damage through homologous recombination (backup repair system)
3. Cancer cells in BRCA mutation carriers already lack working BRCA repair so they cannot use backup system
4. DNA damage accumulates in cancer cells until they have too many errors to survive
5. Cancer cells die while normal cells survive because they have working BRCA repair

SAFETY WATCH

Causes low blood counts: anemia (low red cells), dangerously low infection-fighting cells (neutropenia) (low infection-fighting white cells), a low platelet count (thrombocytopenia) (low platelets) · Can cause new blood cancers (myelodysplastic syndrome, acute leukemia) in 1-2% after long-term use · Causes severe nausea, vomiting, fatigue in first weeks; may need dose reduction · Cannot use in pregnancy; both men and women must use contraception during treatment

Oral contraceptives (birth control pills containing estrogen and progestin) · Combined hormonal contraceptive

Birth control pills reduce ovarian cancer risk by 40-50% in BRCA carriers by stopping ovulation (egg release). Each ovulation creates small tears in ovary surface that must repair, and repeated repair increases cancer chance. Pills also thin the fallopian tube lining where many ovarian cancers actually start.

1. Estrogen and progestin in pills signal pituitary gland (brain gland) to stop making FSH and LH hormones
2. Without FSH and LH, ovaries do not develop follicles (egg-containing sacs) each month
3. Ovulation stops so ovary surface does not tear and repair repeatedly
4. Fewer ovulation cycles over lifetime means lower ovarian cancer risk
5. Pills may slightly increase breast cancer risk but large benefit for ovarian cancer prevention

SAFETY WATCH

Increases blood clot risk especially in smokers over age 35 or those with clotting disorders · May slightly increase breast cancer risk (10-20%) in current users but large ovarian cancer benefit · Not recommended after age 35 in BRCA carriers due to competing breast cancer risk · Stop 4 weeks before major surgery to reduce blood clot risk

Enhanced surveillance (MRI and mammogram alternating) · Non-drug screening protocol

Enhanced surveillance uses breast MRI every 6 months alternating with mammogram to catch breast cancers at earliest stage when cure rate is highest. MRI detects cancers in dense breast tissue of young women that mammogram misses. Early detection improves survival but does not prevent cancer from occurring.

1. MRI uses magnetic field and contrast dye to show blood vessel patterns; cancers grow new vessels so they light up
2. Mammogram uses low-dose x-rays to detect calcium deposits and masses that MRI may miss
3. Alternating tests every 6 months means breast is imaged 4 times per year with different technologies
4. Combination detects 90-95% of breast cancers versus 30-40% with mammogram alone in high-risk women
5. Earlier detection allows breast-conserving surgery and less chemotherapy with better survival

SAFETY WATCH

MRI requires IV gadolinium contrast which can cause allergic reactions in 1-2% · High false-positive rate (10-15%) leads to unnecessary biopsies and anxiety · Radiation exposure from annual mammograms is very low but cumulative over decades · Surveillance misses 5-10% of cancers including interval cancers (those appearing between screenings)

Risk-reducing bilateral salpingo-oophorectomy surgery · Surgical prevention

Removing fallopian tubes and ovaries eliminates the tissue where most hereditary ovarian cancers start. Many ovarian cancers actually begin in fallopian tube tips and spread to ovaries. Surgery also reduces breast cancer risk by 50% if done before menopause because ovaries make estrogen that can fuel breast cancer growth.

1. Surgery removes both fallopian tubes where genetic damage first causes cells to become cancerous

2. Removes both ovaries which can develop cancer and produce estrogen that stimulates breast tissue
3. Eliminating ovaries stops estrogen production causing immediate menopause if premenopausal
4. Lower lifetime estrogen exposure reduces breast cancer risk by half if done before natural menopause
5. Small cancer risk remains because peritoneal cells lining abdomen came from same embryonic tissue as ovaries

SAFETY WATCH

Causes immediate menopause with severe hot flashes, night sweats, vaginal dryness if premenopausal · Increases heart disease and osteoporosis (bone thinning) risk if done before age 45 without hormone replacement · Can use short-term estrogen replacement after surgery until age 50-51 without reducing breast cancer benefit · Surgical risks include bleeding, infection, damage to bladder or bowel (rare, under 1%)

Platinum chemotherapy (cisplatin or carboplatin) · DNA-damaging chemotherapy

Platinum drugs damage DNA in all rapidly dividing cells. BRCA mutation carriers have defective DNA repair, so their cancer cells cannot fix platinum damage and die. Normal cells can repair damage better. Platinum is especially effective in BRCA-related cancers for breast, ovarian, and pancreatic tumors that have already developed.

1. Platinum drug enters all cells and binds to DNA strands creating crosslinks (connections between DNA strands)
2. Crosslinks prevent DNA from unzipping so cells cannot copy their DNA or make proteins
3. Normal cells use BRCA1/BRCA2 and other proteins to cut out and repair platinum-DNA crosslinks
4. Cancer cells in BRCA carriers lack working BRCA repair so crosslinks accumulate
5. Cancer cells with too much DNA damage trigger apoptosis (programmed cell death)

SAFETY WATCH

Severe nausea and vomiting requiring anti-nausea medications with each treatment · Causes low blood counts increasing infection risk (neutropenia), anemia, bleeding risk (thrombocytopenia) · Kidney damage especially with cisplatin; requires IV fluids and careful dosing · Nerve damage (peripheral neuropathy) causing numbness, tingling, pain in hands and feet; may be permanent

Red flags

- Family history of breast cancer before age 50 or ovarian cancer at any age (suggests hereditary mutation requiring genetic counseling)
- Male relative with breast cancer or personal/family history of pancreatic cancer (strongly suggests BRCA2 mutation)
- New breast mass, persistent nipple discharge, or palpable axillary lymph nodes (requires urgent imaging within 2 weeks)
- Abdominal bloating, pelvic pain, early satiety, or increased abdominal size in BRCA carrier (ovarian cancer symptoms requiring urgent ultrasound and CA-125)

Nursing priorities

1. Identify patients with strong family history of breast, ovarian, pancreatic, or prostate cancer for genetic counseling referral — BRCA mutations (changes in genes that increase cancer risk) are inherited; early identification allows cascade testing (testing family members) and risk-reducing interventions before cancer develops.
2. Support patients through genetic testing decision-making and informed consent process — Testing has profound implications for the patient and blood relatives; informed consent must address psychological impact, insurance discrimination concerns under GINA (Genetic Information Nondiscrimination Act), and family disclosure.
3. Coordinate multidisciplinary care including medical oncology, surgical oncology, and reproductive specialists — BRCA carriers need individualized surveillance (regular monitoring for cancer), risk-reducing surgeries (mastectomy or oophorectomy), and fertility preservation counseling before preventive oophorectomy (removal of ovaries).
4. Educate on lifetime cancer risks: 45-70% breast cancer, 11-40% ovarian cancer by age 70 in BRCA carriers — Understanding personal risk empowers shared decision-making about intensive surveillance versus risk-reducing surgeries; BRCA1 carriers face higher ovarian cancer risk than BRCA2.
5. Implement enhanced surveillance protocols for carriers who defer risk-reducing surgery — Surveillance includes breast MRI and mammography alternating every 6 months starting age 25-30, CA-125 (ovarian tumor marker) and transvaginal ultrasound every 6 months, though these do not reduce ovarian cancer mortality like salpingo-oophorectomy does.
6. Provide pre- and post-operative support for patients choosing risk-reducing bilateral mastectomy or salpingo-oophorectomy — Risk-reducing bilateral mastectomy (RRBM) reduces breast cancer risk by 90%; salpingo-oophorectomy by age 35-40 after childbearing reduces ovarian cancer risk by 80% and breast cancer risk by 50% but causes surgical menopause.

7. Address psychosocial and body image concerns related to preventive (prophylactic) surgeries and premature menopause — Bilateral mastectomy and early menopause profoundly affect sexuality, fertility, bone health, and self-image; mental health support and menopausal symptom management (short-term HRT until natural menopause age) are essential.
8. Educate male BRCA carriers about increased prostate, pancreatic, and male breast cancer risks — BRCA2 carriers face 20% lifetime prostate cancer risk and earlier, more aggressive disease; male breast cancer risk is 1-10%; men also pass mutations to children and need family planning counseling.

Sources

- National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic (Version 3.2024)
- American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin No. 182: Hereditary Breast and Ovarian Cancer Syndrome (2017, Reaffirmed 2023)
- American Society of Clinical Oncology (ASCO) Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility (2020)
- U.S. Preventive Services Task Force (USPSTF) Recommendation Statement: Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer (2019)

Last reviewed: 2026-08-29